期刊
CLINICAL INFECTIOUS DISEASES
卷 51, 期 -, 页码 S42-S47出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/653048
关键词
-
资金
- Cerexa/Forest
- Ortho-McNeil
- Pfizer
- Boehringer Ingelheim
- Tibotec
- Wyeth
- Glaxo SmithLkine
- Protez/Novartis
- Merck
- Nabriva
- US Food and Drug Administration
- Infectious Diseases Society of America
- American College of Chest Physicians
- American Thoracic Society
- Society of Critical Care Medicine
- Pharmaceutical Research and Manufacturers of America
- AstraZeneca Pharmaceuticals
- Forest Pharmaceuticals
Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future clinical trials. Despite some differences (mostly related to likely pathogens), there is a general agreement about the recommended approach to management. All of the reviewed guidelines invariably recommend early, appropriate antimicrobial therapy and avoidance of excessive antimicrobials by deescalation of therapy on the basis of microbiological culture results and the clinical response of the patient. Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据